

Presentation #	Presentation Dates	Time	Abstract Title	Presenting Author
POD01	Thursday, February 29, 2024	8:00:00 AM	Specific Symptom Clusters at Diagnosis Signal a Poorer Early Ra Prognosis on Mtx Treatment: Results from The Canadian Early Arthritis Cohort	Susan Bartlett
POD02	Thursday, February 29, 2024	8:00:00 AM	Incidence of Autoimmune Rheumatic Diseases Following Exposure to Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors: a Population-Based Study	Derin Karacabeyli
POD03	Thursday, February 29, 2024	8:00:00 AM	Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-Risk First-Degree Relatives	Liam O'Neil
POD04	Thursday, February 29, 2024	8:00:00 AM	Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus	Caseng Zhang
POD05	Thursday, February 29, 2024	8:00:00 AM	Association of Trimethoprim Sulfamethoxazole Prophylaxis with Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: a Population-Based Study	Arielle Mendel
POD06	Thursday, February 29, 2024	8:00:00 AM	Autoantibodies Against Myxovirus Resistance Protein 1 Are Associated with Myositis and Interstitial Lung Disease in Systemic Lupus	Eugene Krustev
POD07	Thursday, February 29, 2024	8:00:00 AM	Associations Between Disease Activity, Physical Function and Anti-Rheumatic Medications with All-Cause Mortality in Rheumatoid Arthritis (Ra): Data from a Canadian Ra Registry	Sibel Aydin
POD08	Friday, March 1, 2024	8:00:00 AM	Survival on Treatment After Transition to a Biosimilar: Population-Based Evidence from a Natural Experiment Due to a Policy Change	Kasra Moolooghy
POD09	Friday, March 1, 2024	8:00:00 AM	Mesenchymal Stromal Cells in Scleroderma Have an Incomplete Myofibroblast-Like Phenotype with Preserved in Vitro Anti-Inflammatory and Anti-Fibrotic Effects	Ines Colmegna
POD10	Friday, March 1, 2024	8:00:00 AM	Equity, Diversity, and Inclusion in Canadian Rheumatology Research: a Qualitative Study Exploring Researcher Perspectives	Megan Thomas
POD11	Friday, March 1, 2024	8:00:00 AM	Does 18F-Fluorodeoxyglucose Positron Emission Tomography (Pet) Correlate with Disease Activity in Patients Who Are Receiving Treatment for Giant Cell Arteritis (Gca): a Systematic Review and Meta-Analysis	Alison H. Clifford
POD12	Friday, March 1, 2024	8:00:00 AM	Elevated Serum Levels of S100A8/a9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment	Carolina Munoz-Grajales
POD13	Friday, March 1, 2024	8:00:00 AM	Treat (Depression to Reach)-To-Target in Rheumatoid Arthritis	Elliot Hepworth
POD14	Friday, March 1, 2024	8:00:00 AM	Improving Access to Temporal Artery Biopsy for Giant Cell Arteritis Patients	Hillary Chan